NCT05488132

Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Application of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Xuzhou Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of anti-Siglec-6 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.

Detailed description

Sialic acid-binding immunoglobulin-like lectins (Siglec) are a class of classical immunoglobulin-like lectins. Studies have shown that Siglec-6 is commonly expressed in AML but not detected on normal hematopoietic stem and progenitor cells (HSC/P). In vitro experiments revealed that anti-Siglec-6 CAR-T cell treatment did not affect the viability or lineage differentiation in colony-forming assays. These data suggest that anti-SigLlec-6 is an ideal target with great potential for treating acute myeloid leukemia.

Conditions

• Acute Myeloid Leukemia Refractory
• Acute Myeloid Leukemia, in Relapse

Interventions

Type	Name	Description
DRUG	anti-siglec-6 CAR-T cell therapy	Enrolled patients will receive prespecified dose of autologous CAR-T cells.

Timeline

• Start date: 2022-04-01
• Primary completion: 2024-03-31
• Completion: 2025-03-31
• First posted: 2022-08-04
• Last updated: 2022-08-04

Locations

1 site across 1 country: China